Prescriptive authority for psychologists movement

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search

The Prescriptive authority for psychologists (RxP) movement is a political effort to give prescriptive authority to clinical psychologists, enabling them to prescribe psychotropic medications to treat mental and emotional disorders. Prior to RxP legislation and in states where it has not been passed, this role is played by psychiatrists, who possess a medical degree and thus the authority to prescribe medication. The movement is a reaction to the growing public need for mental health services, particularly in less urbanized and therefore under-resourced areas where patients have little or no access to psychiatrists. [1]

In states where RxP legislation has been passed, psychologists who wish to be granted prescriptive authority must possess a doctoral level degree (PhD/PsyD) and a license to practice, and undergo rigorous post-doctoral education and training. The medications they may prescribe are limited to those indicated for mental and emotional health problems; the specific list of approved medications differs by state. The psychologist is required to collaborate with a physician on treatment.

Contents

Supporting arguments

There are several core arguments put forth by RxP advocates, including the following:

  • Other non-physicians have prescription privileges, such as optometrists, nurse practitioners, physician's assistants, and pharmacists.[1]
  • The training model is proven based on a complete lack of legal complaint after eight years regarding the practice of the initial ten psychologists trained by the U.S. Department of Defense.[1]
  • Access to medication would be immediate as opposed to long waiting times that are sometimes necessary to see a specialist.[1]
  • It would not come at the expense of adequate training in the science of psychology, assessment, or psychotherapy because such education would be post-doctoral.[1]
  • It would address the fact that many lack access to psychiatrists (especially in rural areas) and must therefore look to general practitioners who are generally under-trained regarding psychotropic medications.[1][1]
  • It would make a clear separation between doctoral and masters-level practitioners.[1]
  • It would allow the psychologist control of the entire treatment process, which would avoid the complications of interprofessional collaboration while also saving clients money.[1]
  • Adding competence to consult with general practitioners who need professional advice regarding psychotropic medications.[1]
  • Psychopharmaceutical training allows for better client advocacy.[1]

Opposition

Opponents argue that the required training programs are too short and that psychologists completing this training will not be adequately equipped to understand the biomedical effects of a medication and thus anticipate possible adverse reactions, interactions with other medications or side effects, thus putting patient safety at risk. [1]

Additionally, critics express concern that, if RxP became the norm, the biomedical approach would begin to encroach on the traditional psychology curriculum and clinicians in training would receive less grounding in psychotherapeutic interventions and research. [1]

History

In 1988, the U.S. Department of Defense approved a pilot project to train psychologists in issuing psychotropic medications "under certain circumstances". Guam became the first U.S. territory to approve RxP legislation in 1999. New Mexico became the first state to approve RxP legislation in 2002, and Louisiana followed in 2004. As of April 2007, 5 other states have introduced RxP bills that are under discussion but have yet to be approved. [1] [1]

References


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools